Brussels, 1 mar (EFE).-the European Commission (EC) announced today the closing of its research on drug companies AstraZeneca and Nycomed, to not have found evidence that he had acted to prevent the access of generics to the market.
Research “could not establish any infringement”, that “there was no evidence”, said a community spokesman in a statement to the press.
The EC took place on November 30, 2010 inspections unannounced at AstraZeneca offices in different countries of the European Union (EU).
The EU Executive launched extensive research in the pharmaceutical sector as a whole to try to find out if some companies were slowing the arrival on the market of generic to reduce their profit margin between 2008 and 2009.
Some of these antitrust investigations are still underway, as he recalled the EC said in a statement. EFE
